Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eldelumab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Eldelumab (BMS-936557) is a fully human IgG1 kappa monoclonal antibody that targets the chemokine CXCL10 (also known as Interferon-γ-inducible protein 10 or IP-10). By binding to CXCL10, eldelumab inhibits its interaction with the CXCR3 receptor and blocks IP-10-induced chemotaxis of activated T cells. This mechanism is intended to reduce inflammatory cell migration and modulate immune responses in diseases characterized by elevated CXCL10 levels. Eldelumab was developed for the treatment of autoimmune and inflammatory conditions such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, and spinal cord injuries. Clinical trials demonstrated safety but did not meet primary efficacy endpoints in ulcerative colitis or Crohn’s disease[1][2][4][5][6].
- Other names
- Anti-CXCL10 antibodyAnti-CXCL-10 antibodyAnti-CXCL 10 antibody
02
Targets
CXCL10 (C-X-C Motif Chemokine Ligand 10)
Beyond the preview
Go deeper on eldelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eldelumab.